EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants

Cheng Cui, Xiaoye Niu, Haiyan Li, Ruijie Zhang, Lei Geng, Wei Lin, Zichen Liu, Xiaohong Wang, Dongyang Liu

Clinical Drug Investigation · 2025

DOI: 10.1007/s40261-025-01428-9 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Drug Investigation, 2025. Verfasst von Cheng Cui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China. Hauptthemen laut MEDLINE: Hypoxia-Inducible Factor-Proline Dioxygenases, N-substituted Glycines, Prolyl-Hydroxylase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Enarodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor. We evaluated the pharmacokinetics, pharmacodynamics, and safety profile of domestic enarodustat (SAL-0951) and analyzed the influence of ethnic factors. METHODS: In this phase I study, healthy Chinese participants received single and multiple oral doses (1, 5, and 15 mg) of SAL-0951 while in a fasted state. We monitored the pharmacokinetics, pharmacodynamics, and safety characteristics and analyzed the impact of ethnicity on pharmacokinetic characteristics. RESULTS: In total, 33 healthy Chinese participants were enrolled; the mean age was 31.2 ± a standard deviation of 5.5 years. After single doses of 1, 5, and 15 mg were administered under fasted conditions, SAL-0951 was rapidly absorbed. Mean maximum plasma concentration and area under the plasma concentration-time curve from time 0 to the last quantifiable concentration increased dose proportionately from 0.14 to 2.54 μg/mL and from 0.63 to 9.50 h × μg/mL, respectively. The elimination half-life was 6.13, 6.32, and 6.74 h, respectively, in these three groups, and the mean value of apparent clearance ranged from 1.64 to 1.89 L/h. SAL-0951 was excreted mostly as the parent compound. It reached a stable concentration after 5 days of multiple-dose administration. We observed no drug accumulation or time-dependent pharmacokinetic characteristics and no significant difference in pharmacokinetic characteristics between Chinese and Japanese participants. CONCLUSION: SAL-0951 was safe and well tolerated in healthy Chinese participants and had a linear pharmacokinetic profile. We found no ethnic differences in the pharmacokinetic characteristics of the drug between Chinese and Japanese populations. CLINICAL TRIAL REGISTRATION: Registered at Chinadrugtrials.org.cn, registration number CTR2020245.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoxia-Inducible Factor-Proline DioxygenasesN-substituted GlycinesProlyl-Hydroxylase InhibitorsHumansAdultMaleFemaleYoung AdultHealthy VolunteersAdministration, OralDose-Response Relationship, DrugArea Under CurvePyridinesTriazolesEast Asian People

Substanzen

enarodustatHypoxia-Inducible Factor-Proline DioxygenasesN-substituted GlycinesProlyl-Hydroxylase InhibitorsPyridinesTriazoles

Autor:innen und Institutionen

  • Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China.
  • Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China.
  • Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.
  • Department of Clinical Pharmacology, Shenzhen Salubris Pharmaceuticals Co. Ltd, Beijing, 100022, China.
  • Department of Clinical Operations, Shenzhen Salubris Pharmaceuticals Co. Ltd, Shenzhen, 518000, China.
  • Department of Data Science, Shenzhen Salubris Pharmaceuticals Co. Ltd, Beijing, 100022, China.

Zitieren

APA

Cui, C., Niu, X., Li, H., Zhang, R., Geng, L., Lin, W., Liu, Z., Wang, X., & Liu, D. (2025). Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01428-9

Vancouver

Cui C, Niu X, Li H, Zhang R, Geng L, Lin W, et al. Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants. Clinical Drug Investigation. 2025. doi:10.1007/s40261-025-01428-9

BibTeX
@article{Cui2025,
  author = {Cui, Cheng and Niu, Xiaoye and Li, Haiyan and Zhang, Ruijie and Geng, Lei and Lin, Wei and Liu, Zichen and Wang, Xiaohong and Liu, Dongyang},
  title = {Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants},
  journal = {Clinical Drug Investigation},
  year = {2025},
  doi = {10.1007/s40261-025-01428-9}
}
Kostenlos starten →